For most small and mid-size biotech companies, getting to first-in-human (FIH) dosing as quickly as possible is an existential priority. Clinical data is the currency of biotech fundraising. Every month between selecting a candidate and dosing the first patient in a Phase I study is a month during which a competitor may be generating data, a month during which your runway is shortening, and a month during which your thesis is untested.
Compressing the FIH timeline is not about cutting corners. It is about identifying the activities that are on the critical path, running parallel workstreams where the science allows, and building a development plan that avoids the common causes of delay.
Where Time Is Actually Lost
| Stage | Common Delay Cause | Typical Time Lost |
| Pre-formulation | Solid-state screening not started until API is available | 4-8 weeks |
| Formulation development | Sequential rather than parallel solubility and stability work | 6-12 weeks |
| Analytical method development | GMP-level methods designed before formulation is stable | 4-8 weeks |
| CMC dossier preparation | Regulatory writing starts late, after all data is available | 4-8 weeks |
| GMP manufacturing | CDMO slot not reserved in advance, tech transfer takes longer than expected | 8-16 weeks |
| IND/IMPD review | CMC deficiencies due to incomplete or inconsistent data | 3-6 months (FDA response cycle) |
Strategies for Compressing the Timeline
Start Solid-State Work Before the API Synthesis Is Complete
Polymorph screening and salt selection require API material, but they do not require final, fully characterised API at commercial purity. Starting with earlier-stage material from chemical development and running solid-state work in parallel with final synthesis optimisation can save four to six weeks without adding scientific risk, provided the synthetic route is sufficiently stable.
Use a Formulation-First Mindset
The target product profile should drive formulation strategy from day one. If you know the target dose, the intended patient population, and the required release profile before pre-formulation begins, the screening work is more focused. Bioavailability-enhancing technologies such as amorphous solid dispersions or nanosuspensions should be evaluated in parallel with simpler approaches rather than as a sequential fallback. ICH Q8(R2) on pharmaceutical development describes the design space concept that supports this structured, front-loaded approach.
Develop Methods Fit for Purpose, Not Fit for Filing
A common source of wasted time is developing fully validated GMP analytical methods before the formulation is stable. Early development analytical methods need to be accurate, reproducible, and suitable for the decisions being made at that stage. They do not need to meet the validation criteria required for GMP release until the formulation and process are sufficiently locked. Phasing method development appropriately frees capacity and avoids rework.
Book Your GMP Slot Before You Need It
GMP manufacturing capacity at reputable CDMOs is typically booked six to twelve months in advance. If you wait until your formulation is finalised before engaging with a manufacturing partner, you will wait. Engaging early, sharing your development timeline, and reserving a provisional slot before the technical package is complete is standard practice for programmes with aggressive timelines.
Write the CMC Section Progressively
The CMC section of an IND or IMPD does not have to be written in one sprint at the end of development. A regulatory team that is integrated with the development programme writes sections as the data is generated, so that by the time the last experiment is complete, the dossier is 80% written. This approach also surfaces regulatory questions early, when there is still time to address them without delaying the filing.
How Ardena Builds Speed into Development Programmes
Ardena’s integrated model is specifically designed to support compressed FIH timelines. The solid-state team, formulation scientists, analytical chemists, and regulatory advisors work on the same programme, sharing data in real time and making decisions together rather than sequentially. GMP manufacturing capacity at Ardena’s sites can be provisionally reserved as part of the development agreement, removing the CDMO slot booking risk from your critical path.
